BioMarin announced five-year Phase 3 trial results showing its combination therapy, Pombiliti and Opfolda, helped adults with late-onset Pompe disease maintain walking distance and stable respiratory function over continuous treatment. The study included 82 patients and found no new safety concerns. This data supports BioMarin's expanded role in rare metabolic diseases following its acquisition of Amicus Therapeutics, which marketed the therapy. The findings were presented at the World Muscle Society Congress, highlighting long-term benefits for this progressive muscle-weakening condition.
BioMarin's five-year Pompe disease data is the focus here, with Pluang's Health sector market snapshot as of Oct 02, 2026 23:13 WIB showing that out of 100 priced US Health stocks, 43 advanced while 55 declined. Notable movers include Oscar Health Inc (OSCR) at USD 30.70 with a 1-day change of +2.68% and Tenet Healthcare Corporation (THC) at USD 260.25 with +2.47%, while Sanofi SA (SNY) fell by -2.32% to USD 39.73, with typical hold times ranging from 15 to 94 days on Pluang.
NextEra Energy and partners are developing Project Star, a $22.3 billion natural gas-powered energy campus in Encinal, Texas, aimed at powering a large data center and supplying the grid. The campus will have 6.47 gigawatts of generation capacity, wi...
UBS has increased its price target for G-III Apparel Group to $27.00 from $26.00, reflecting confidence in the company's financial health and market position. Although the current share price slightly exceeds UBS's target, other analysts see potentia...
Enerflex secured a contract to build about 450 megawatts of natural gas-fired power units for a North American data center developer, with deliveries starting in 2027 and completing in 2028. The company’s 2026 capital spending includes $15 million fo...
UBS lowered its price target for McCormick from $52 to $48 following the company's Q3 fiscal 2026 results. Although McCormick beat expectations and confirmed its full-year outlook, its net income fell sharply to $97.6 million from $225.5 million year...
TransUnion has announced that its VantageScore 4.0 mortgage scores will be priced at $0.99 each until December 2028, providing stable and predictable costs for lenders. This pricing strategy follows the Federal Housing Finance Agency's decision to ex...
